Is interleukin-6 gene -174 promoter polymorphism associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis?
Our results support a role of IL6 -174 gene polymorphism in the development of subclinical atherosclerosis in patients with RA.
The use of ML to stratify patients with NDBE by risk was the most cost-effective strategy for preventive EAC treatment. Targeting ablation toward patients with high ML presents an opportunity for a paradigm shift in the management of NDBE.